Literature DB >> 16523403

Neramexane (merz pharmaceuticals/forest laboratories).

Gerhard Rammes1, Anja Schierloh.   

Abstract

Merz Pharmaceuticals GmbH and Forest Laboratories Inc are developing neramexane, an oral N-methyl-D-aspartate antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16523403

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  3 in total

Review 1.  The nicotinic receptor of cochlear hair cells: a possible pharmacotherapeutic target?

Authors:  Ana Belén Elgoyhen; Eleonora Katz; Paul A Fuchs
Journal:  Biochem Pharmacol       Date:  2009-05-27       Impact factor: 5.858

Review 2.  NMDA receptors in clinical neurology: excitatory times ahead.

Authors:  Lorraine V Kalia; Suneil K Kalia; Michael W Salter
Journal:  Lancet Neurol       Date:  2008-08       Impact factor: 44.182

3.  Investigational drugs for the treatment of AD: what can we learn from negative trials?

Authors:  Sandra A Jacobson; Marwan N Sabbagh
Journal:  Alzheimers Res Ther       Date:  2011-04-15       Impact factor: 6.982
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.